Work

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Year: 2015

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v126.23.3795.3795

Authors: Kendra L. Sweet, Naveen Pemmaraju, Andrew A Lane, Anthony S. Stein, Sumithira Vasu, William Blum, David A. Rizzieri, Eunice S. Wang, Eric K. Rowinsky, Michael Szarek, Christopher L. Brooks, Sarah Disalvatore, David Liu, Madeleine Duvic, Jonathan D. Schwartz, Marina Konopleva

Institutions: Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, City Of Hope National Medical Center, The Ohio State University, Duke Medical Center, Roswell Park Comprehensive Cancer Center, Stemline Therapeutics (United States)

Language: English

Topic: Toxin Mechanisms and Immunotoxins

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2583358631

FWCI: 1.512

Cites:

Cited by: 18

Related to: 10